K-STREET TRACKER
FOLLOW THE MONEY INTO THE SWAMP
Every federal lobbying filing tagged with a public-company ticker — who is spending, which firms they hire, and which members trade right around the filing.
Filings tracked
19,882
thru 2026-05-08
Total reported $
$2.7B
disclosed lobbying
Distinct clients
2,220
paying companies
Tickers targeted
1,207
public companies
💸 Top Spending Clients
| # | Client | Filings | Total $ |
|---|---|---|---|
| 1 |  PFIZER INC.PFE | 47 | $46.8M |
| 2 |  GENERAL MOTORS COMPANYGM | 61 | $46.8M |
| 3 |  META PLATFORMS INC. AND VARIOUS SUBSIDIARIESMETA | 12 | $44.9M |
| 4 | VISA INC.V | 45 | $37.7M |
| 5 |  AMAZON.COM SERVICES LLCAMZN | 36 | $32.8M |
| 6 |  LOCKHEED MARTIN CORPORATIONLMT | 73 | $29.0M |
| 7 |  FEDEX CORPORATIONFDX | 69 | $27.8M |
| 8 |  ELI LILLY AND COMPANYLLY | 56 | $27.1M |
| 9 |  ALTRIA CLIENT SERVICES LLCMO | 142 | $25.2M |
| 10 |  AMGEN INCAMGN | 19 | $24.9M |
| 11 |  COMCAST CORPORATIONCMCSV | 179 | $24.7M |
| 12 |  MERCK & CO INCMRK | 14 | $24.0M |
| 13 |  SOUTHERN COMPANYSO | 53 | $23.9M |
| 14 |  GOOGLE CLIENT SERVICES LLCGOOGL | 79 | $22.6M |
| 15 |  APPLE INCAAPL | 9 | $22.1M |
| 16 |  T-MOBILE USA INC.TMUS | 121 | $21.0M |
| 17 |  UNITEDHEALTH GROUP INCUNH | 19 | $20.4M |
| 18 |  VERIZON COMMUNICATIONS INC AND VARIOUS SUBSIDIARIESVZ | 40 | $20.1M |
| 19 |  OCCIDENTAL PETROLEUM CORPORATIONOXY | 30 | $19.7M |
| 20 |  MICROSOFT CORPORATIONMSFT | 103 | $18.8M |
| 21 |  QUALCOMM INCORPORATEDQCOM | 40 | $17.2M |
| 22 |  GENERAL DYNAMICS CORPGD | 11 | $17.0M |
| 23 |  BOEING COMPANYBA | 23 | $16.9M |
| 24 | THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)CI | 13 | $16.9M |
| 25 |  ORACLE CORPORATIONORCL | 58 | $16.7M |
🎯 Top Lobbied Tickers
| # | Ticker | Filings | Total $ |
|---|---|---|---|
| 1 | META Meta Platforms Inc. | 129 | $50.2M |
| 2 | PFE Pfizer Inc. | 87 | $48.6M |
| 3 | GM General Motors Company | 103 | $48.4M |
| 4 | V Visa Inc. | 46 | $37.7M |
| 5 | AMZN Amazon.com Inc. | 80 | $35.3M |
| 6 | LMT Lockheed Martin Corporation | 88 | $29.4M |
| 7 | FDX FedEx Corporation | 82 | $28.3M |
| 8 | LLY Eli Lilly and Company | 83 | $28.1M |
| 9 | AMGN Amgen Inc. | 95 | $28.0M |
| 10 | MRK Merck & Co. Inc. | 92 | $27.5M |
| 11 | AAPL Apple Inc. | 64 | $26.8M |
| 12 | GOOGL Alphabet Inc. Class A | 123 | $26.6M |
| 13 | MO | 164 | $26.2M |
| 14 | SO Southern Company | 108 | $26.1M |
| 15 | UNH UnitedHealth Group Inc. | 67 | $23.9M |
| 16 | VZ Verizon Communications Inc. | 116 | $23.8M |
| 17 | TMUS | 159 | $22.7M |
| 18 |  CHTR | 137 | $22.6M |
| 19 | GD General Dynamics Corporation | 127 | $22.5M |
| 20 |  TAT&T Inc. | 134 | $21.6M |
| 21 | ORCL Oracle Corporation | 132 | $20.6M |
| 22 | CMCSA Comcast Corporation | 141 | $20.4M |
| 23 | CI The Cigna Group | 64 | $19.9M |
| 24 | OXY Occidental Petroleum Corporation | 36 | $19.9M |
| 25 | MSFT Microsoft Corporation | 122 | $19.2M |
🆕 Filtered Filings · SRPT
clear filters| Date | Ticker | Client | Registrant | Amount | Issue |
|---|---|---|---|---|---|
| 2026-04-20 | SRPT | SAREPTA THERAPEUTICS INC. | SAREPTA THERAPEUTICS, INC. | $270K | Duchenne Muscular Dystrophy and Rare Disease Patient Access to Treatments Newborn Screening for Rare Diseases Scientific Innovation in Healthcare Gene Therapies Artificial Intelligence and Data Governance |
| 2026-04-20 | SRPT | SAREPTA THERAPEUTICS | MICHAEL BEST STRATEGIES LLC | $110K | Scientific innovation in healthcare including gene therapy, rare diseases including Duchenne muscular dystrophy Scientific innovation in healthcare including gene therapy, rare diseases including Duchenne muscular dystrophy |
| 2026-04-20 | SRPT | SAREPTA THERAPEUTICS | TARPLIN, DOWNS & YOUNG, LLC | $90K | federal budget issues innovation, Duchenne Muscular Dystrophy, platform technologies, value based contracting, gene therapy Medicaid drug rebate program, coverage, state program operations, waivers, gene therapy, value based contracting |
| 2026-01-20 | SRPT | SAREPTA THERAPEUTICS INC. | SAREPTA THERAPEUTICS, INC. | $230K | Patient Access to Treatments Newborn Screening for Rare Diseases Scientific Innovation in Healthcare Gene Therapies Rare Diseases Artificial Intelligence and Data Governance |
| 2026-01-20 | SRPT | SAREPTA THERAPEUTICS | MICHAEL BEST STRATEGIES LLC | $110K | Scientific innovation in healthcare including gene therapy, rare diseases including Duchenne muscular dystrophy Scientific innovation in healthcare including gene therapy, rare diseases including Duchenne muscular dystrophy |
| 2026-01-20 | SRPT | SAREPTA THERAPEUTICS | TARPLIN, DOWNS & YOUNG, LLC | $90K | federal budget issues innovation, Duchenne Muscular Dystrophy, platform technologies, value based contracting, gene therapy Medicaid drug rebate program, coverage, state program operations, waivers, gene therapy, value based contracting |
| 2025-10-20 | SRPT | SAREPTA THERAPEUTICS | MICHAEL BEST STRATEGIES LLC | $110K | Scientific innovation in healthcare including gene therapy, rare diseases including Duchenne muscular dystrophy Scientific innovation in healthcare including gene therapy, rare diseases including Duchenne muscular dystrophy |
| 2025-10-20 | SRPT | SAREPTA THERAPEUTICS | TARPLIN, DOWNS & YOUNG, LLC | $80K | federal budget issues innovation, Duchenne Muscular Dystrophy, platform technologies, value based contracting, gene therapy Medicaid drug rebate program, coverage, state program operations, waivers, gene therapy, value based contracting, Medicaid value based payment rule |
| 2025-10-15 | SRPT | SAREPTA THERAPEUTICS INC. | SAREPTA THERAPEUTICS, INC. | $430K | Issues related to patient access to treatments Issues related to rare diseases such as Duchenne Muscular Dystrophy Issues related to newborn screening for rare diseases Issues related to the Inflation Reduction Act's prescription drug provisions Issues related to scientific innovation in healthcare such as gene therapies Issues related to artificial intelligence and data governance Tax issues related to research and development |
| 2025-07-21 | SRPT | SAREPTA THERAPEUTICS | TARPLIN, DOWNS & YOUNG, LLC | $80K | federal budget issues innovation, Duchenne Muscular Dystrophy, platform technologies, value based contracting, gene therapy Medicaid drug rebate program, coverage, state program operations, waivers, gene therapy, value based contracting, Medicaid value based payment rule |
| 2025-07-21 | SRPT | SAREPTA THERAPEUTICS | MICHAEL BEST STRATEGIES LLC | $40K | Rare disease therapeutic development and access Rare disease therapeutic development and access |
| 2025-07-16 | SRPT | SAREPTA THERAPEUTICS INC. | SAREPTA THERAPEUTICS, INC. | $260K | Issues related to rare diseases such as Duchenne Muscular Dystrophy Issues related to patient access to treatments Issues related to newborn screening for rare diseases Issues related to scientific innovation in healthcare such as gene therapies Issues related to artificial intelligence and data governance Tax issues related to research and development |
| 2025-07-15 | SRPT | SAREPTA THERAPEUTICS | MICHAEL BEST STRATEGIES LLC | $0 | Rare disease therapeutic development and access Rare disease therapeutic development and access |
| 2025-04-20 | SRPT | SAREPTA THERAPEUTICS | TARPLIN, DOWNS & YOUNG, LLC | $80K | federal budget issues innovation, Duchenne Muscular Dystrophy, platform technologies, value based contracting, gene therapy Medicaid drug rebate program, coverage, state program operations, waivers, gene therapy, value based contracting, Medicaid value based payment rule |
| 2025-04-16 | SRPT | SAREPTA THERAPEUTICS INC. | SAREPTA THERAPEUTICS, INC. | $320K | Issues related to patient access to treatments Issues related to rare diseases such as Duchenne Muscular Dystrophy Issues related to newborn screening for rare diseases Issues related to the Inflation Reduction Acts prescription drug provisions Issues related to scientific innovation in healthcare such as gene therapies Issues related to artificial intelligence and data governance Tax issues related to research and development |
| 2025-01-21 | SRPT | SAREPTA THERAPEUTICS | TARPLIN, DOWNS & YOUNG, LLC | $80K | Federal budget issues Innovation, Duchenne Muscular Dystrophy, platform technologies, value based contracting, gene therapy Medicaid drug rebate program, coverage, state program operations, waivers, gene therapy, value based contracting, Medicaid value based payment rule |